image description
image description

Archives


  • 31-10-21

    Saudi Arabia’s Dammam Biotech Valley to go through clinical trials

    (MENAFN)CEO Abdulrahman Alolayan was quoted as saying that Saudi Arabia’s Dammam Biotech Valley will be going through clinical trials to produce its first vaccines in the Kingdom.

    The official also hopes that the trials are going to end in 2022 after which it will be presented to the Saudi Food and Drug Authority for further approval.

    An academic at King Saud University, Alolayan, further stated that the company is looking for international partnerships to produce the vaccine.

    On the sidelines of the Future Investment Initiative summit held in Riyadh this week, he also declared that “We are talking to a number of international partners from Switzerland, India and the UK. Once we finalize it, we will make it public.” The company is simultaneously working on different fronts such as incubating ideas, leading research and investing in startups and other projects, the CEO added.

Follow us

RSS
Terms & Conditions  |  Privacy & Security  |  Contact Us  | Sitemap
© 2024 BBK  |  All Rights Reserved